Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT06742567

Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction

Led by National Institute of Cardiovascular Diseases, Pakistan · Updated on 2024-12-19

472

Participants Needed

1

Research Sites

51 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.

CONDITIONS

Official Title

Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 18 to 65 years
  • Diagnosed with acute anterior STEMI
  • Severe left ventricular dysfunction with ejection fraction below 35%
  • Presence of antero-apical akinesis, dyskinesis, or aneurysm
  • No evidence of left ventricular thrombus
Not Eligible

You will not qualify if you...

  • Previous anterior myocardial infarction or LAD revascularization procedures
  • Cardiogenic shock
  • Existing left ventricular thrombus
  • Advanced chronic kidney disease with creatinine over 2 or on hemodialysis
  • Recent intracranial hemorrhage or major bleeding requiring transfusion
  • Low platelet count below 100,000
  • History of stroke within the past three months
  • Atrial fibrillation or other reasons for ongoing anticoagulation
  • Pregnancy or hematological disorders

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

NICVD Pakistan

Karachi, Sindh, Pakistan

Actively Recruiting

Loading map...

Research Team

A

Abdul Hakeem, MD FACC FSCAI FASE

CONTACT

S

Sabha Bhatti, MD FASE FASNC FACC

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here